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Structure-based discovery of fiber-binding 
compounds that reduce the cytotoxicity 
of amyloid beta
Lin Jiang†, Cong Liu†, David Leibly, Meytal Landau‡a, Minglei Zhao‡b, 
Michael P Hughes, David S Eisenberg*
Departments of Chemistry and Biochemistry and Biological Chemistry, Howard 
Hughes Medical Institute, UCLA–DOE Institute for Genomics and Proteomics, 
University of California, Los Angeles, Los Angeles, United States
Abstract Amyloid protein aggregates are associated with dozens of devastating diseases 
including Alzheimer’s, Parkinson’s, ALS, and diabetes type 2. While structure-based discovery of 
compounds has been effective in combating numerous infectious and metabolic diseases, ignorance 
of amyloid structure has hindered similar approaches to amyloid disease. Here we show that 
knowledge of the atomic structure of one of the adhesive, steric-zipper segments of the amyloid-beta 
(Aβ) protein of Alzheimer’s disease, when coupled with computational methods, identifies eight 
diverse but mainly flat compounds and three compound derivatives that reduce Aβ cytotoxicity 
against mammalian cells by up to 90%. Although these compounds bind to Aβ fibers, they do not 
reduce fiber formation of Aβ. Structure-activity relationship studies of the fiber-binding compounds 
and their derivatives suggest that compound binding increases fiber stability and decreases fiber 
toxicity, perhaps by shifting the equilibrium of Aβ from oligomers to fibers.
DOI: 10.7554/eLife.00857.001
Introduction
Protein aggregates, both amyloid fibers and smaller amyloid oligomers, have been implicated in the 
pathology of Alzheimer’s and other neurodegeneration diseases (Chiti and Dobson, 2006; Eisenberg and 
Jucker, 2012). The increasing prevalence of Alzheimer’s disease in our aging societies, the associated 
tragedy for patients and their families, and the mounting economic burden for governments have all 
stimulated intense research into chemical interventions for this condition. Much work has been focused 
on screening compounds that prevent aggregation and the associated cytotoxicity of the amyloid 
β-peptide (Aβ) (reviews by Sacchettini and Kelly, 2002; Bartolini and Andrisano, 2010; Hard and 
Lendel, 2012).
Screens have often focused on natural products from plants and lichens. These include polyphenols, 
such as epigallocatechin gallate (EGCG) from green tea (Ehrnhoefer et al., 2008) and curcumin from 
the spice turmeric (Yang et al., 2005). These natural polyphenolic compounds show inhibition on the 
fibrillation of a variety of amyloid proteins, including Aβ40 as well as α-synuclein, IAPP and PrP (Porat 
et al., 2006; Dasilva et al., 2010; Ono et al., 2012). Several dyes have also been found to ameliorate 
amyloid toxicity. Orcein from lichens appears to diminish toxic oligomers and enhance fiber formation 
(Bieschke et al., 2011). Congo red, thioflavin T and their analogs, commonly used as staining reagents 
for amyloid detection, exhibit ameliorative effects on neurodegenerative disorders, such as Alzheimer’s, 
Parkinson’s, Huntington’s, and prion diseases (Frid et al., 2007; Alavez et al., 2011), however their 
application is limited by significant side effects (Klunk et al., 2004).
Additional screens have identified a variety of molecules, including proteins (Evans et al., 2006), 
antibodies (Kayed et al., 2003; Ladiwala et al., 2012), synthetic peptide mimetics (Findeis, 2002; 
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Kokkoni et al., 2006; Takahashi and Mihara, 2008; Cheng et al., 2012) and small molecules (Wood 
et al., 1996; Williams et al., 2005; McLaurin et al., 2006; Necula et al., 2007; Bartolini and 
Andrisano, 2010; De Felice et al., 2001; Ladiwala et al., 2011; Hard and Lendel, 2012; Kroth et 
al., 2012), that inhibit Aβ fibrillogenesis and/or Aβ-associated cytotoxicity in vitro. While most efforts 
have targeted the deposition of Aβ fibers as the hallmark of Alzheimer’s, smaller amyloid oligomers 
are now receiving greater attention as the possible toxic entities in Alzheimer’s and other neurode-
generative diseases (Hartley et al., 1999; Cleary et al., 2005; Silveira et al., 2005). Furthermore, 
emerging evidence suggests that mature, end-stage amyloid fibers may serve as a reservoir, prone to 
releasing toxic oligomer (Xue et al., 2009; Cremades et al., 2012; Krishnan et al., 2012; Shahnawaz 
and Soto, 2012). Recent screens have identified compounds that reduce Aβ cytotoxicity, without 
interfering with Aβ fibrillation (Chen et al., 2010) or promoting the formation of stable Aβ aggregates 
(Bieschke et al., 2011).
Structural information about protein targets often aids drug development, so here we take a structure-
based approach, combined with computational screening, to discover amyloid interacting compounds 
that reduce amyloid toxicity. This approach has been enabled by the determination of atomic structures 
of the adhesive segments of amyloid fibers, termed steric zippers (Nelson et al., 2005), and of solid 
state NMR-based structures of amyloid fibers (such as full-length Aβ fibers [Luhrs et al., 2005; Petkova 
et al., 2005] and the HET-s prion domain complexed with Congo Red [Schutz et al., 2011]). The steric 
zipper structures reveal a common motif for the spine of amyloid fibers, in which a pair of fibrillar 
β-sheets is held together by the side-chain interdigitation (Sawaya et al., 2007). We focus on Aβ, 
a peptide of 39–42 residues cleaved from the Amyloid precursor protein (APP) associated with 
Alzheimer’s, as a target for inhibitor discovery. The segment Aβ16–21 with the sequence KLVFFA is an 
amyloid-forming peptide, which packs in a steric zipper form, and has been identified as the spine of 
eLife digest Alzheimer’s disease is the most common form of dementia, estimated to affect 
roughly five million people in the United States, and its incidence is steadily increasing as the 
population ages. A pathological hallmark of Alzheimer’s disease is the presence in the brain of 
aggregates of two proteins: tangles of a protein called tau; and fibers and smaller units (oligomers) 
of a peptide called amyloid beta.
Many attempts have been made to screen libraries of natural and synthetic compounds to 
identify substances that might prevent the aggregation and toxicity of amyloid. Such studies 
revealed that polyphenols found in green tea and in the spice turmeric can inhibit the formation 
of amyloid fibrils. Moreover, a number of dyes reduce the toxic effects of amyloid on cells, 
although significant side effects prevent these from being used as drugs.
Structure-based drug design, in which the structure of a target protein is used to help identify 
compounds that will interact with it, has been used to generate therapeutic agents for a number of 
diseases. Here, Jiang et al. report the first application of this technique in the hunt for compounds 
that inhibit the cytotoxicity of amyloid beta. Using the known atomic structure of the protein in 
complex with a dye, Jiang et al. performed a computational screen of 18,000 compounds in search 
of those that are likely to bind effectively.
The compounds that showed the strongest predicted binding were then tested for their 
ability to interfere with the aggregation of amyloid beta and to protect cells grown in culture 
from its toxic effects. Compounds that reduced toxicity did not reduce the abundance of 
protein aggregates, but they appear to increase the stability of fibrils. This is consistent with 
other evidence suggesting that small, soluble forms (oligomers) of amyloid beta that break  
free from the fibrils may be the toxic agent in Alzheimer’s disease, rather than the fibrils 
themselves.
In addition to uncovering compounds with therapeutic potential in Alzheimer’s disease, this 
work presents a new approach for identifying proteins that bind to amyloid fibrils. Given that 
amyloid accumulation is a feature of many other diseases, including Parkinson’s disease, 
Huntington’s disease and type 2 diabetes, the approach could have broad therapeutic 
applications.
DOI: 10.7554/eLife.00857.002
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the full-length Aβ fiber (Luhrs et al., 2005; Petkova et al., 2006; Colletier et al., 2011). Co-crystal 
structures have been determined for small molecules in complex with the fibrillar β-sheets of Aβ16–21 
(Landau et al., 2011). One of these structures—Aβ16–21 with the dye Orange G—reveals the specific 
pattern of hydrogen bonds and apolar interactions between orange G and the steric zipper: the 
negatively charged dye binds specifically to lysine side chains of adjacent sheets, and its planar 
aromatic portion packs against apolar residues (phenylalanine and valine) of adjacent sheets. By creating 
a tight, low energy interface across several β-strands within fiber core, this fiber-binding molecule 
appears to stabilize the fiber structure. With this atomic structure as a basis, we are able to screen for 
small molecular compounds that bind to amyloid fibers, stabilizing them and possibly reducing 
amyloid toxicity. Applying our structure-based screening procedure, we screen computationally for 
compounds that bind to Aβ fibers, termed BAFs (Binders of Amyloid Fibers) and then experimentally 
test their effects on Aβ aggregation and cytotoxicity.
Results
Structure-based screening procedure
We have devised a structure-based procedure for the identification of small molecules that bind 
to amyloid and affect amyloid toxicity (Figure 1). The procedure starts from a co-crystal structure of a 
ligand bound to an amyloidogenic segment of Aβ (Landau et al., 2011), the dye orange G bound 
to the fiber-like crystal structure of KLVFFA(Aβ16–21) segment. This structure reveals the chemical 
environment or ‘pharmacophore’ presented by the ligand binding site of this Aβ segment, that is, 
orange G binds to stacked β-sheets of Aβ. Knowledge of the amyloid pharmacophore (Figure 1A) 
permitted us to screen for compounds that could be expected to bind in this chemical environment, 
possibly stabilizing amyloid fibers.
Construction of compound libraries for computational screening
For assembling the compounds in our screening library, we sought three characteristics: (a) com-
mercially available compounds since we intended to follow the in silico screening with experimental 
validation; (b) compounds with known three-dimensional structures such that our screening would 
be as realistic as possible; (c) generally flat compounds able to bind to the β-sheets of the steric 
zipper, as does orange G. Some ∼11,000 compounds having the first two characteristics (CSD-ZINC 
set) were selected as the intersection of molecules found both in the Cambridge Structure Database 
(http://www.ccdc.cam.ac.uk) and the Zinc Database of purchasable compounds (http://zinc.docking.
org/) (Irwin and Shoichet, 2005). This CSD-ZINC set spans a variety of structural shapes and molecular 
properties. A second set of ∼7000 compounds, the Flat Compound Set, was gathered from the ZINC 
database to include molecules expected to bind to the flat surface of a steric zipper. The members of 
this set contain multiple aromatic rings or one aromatic ring with additional planar groups.
Computational screening of compounds that bind to Aβ fibers
Computational screening was carried out with the RosettaLigand program (Davis and Baker, 2009), 
after adapting its docking approach to carry out high-throughput screening (Figure 2). The conformational 
flexibilities of ligand and protein side chains are in a ‘near-native’ perturbation fashion, meaning that 
the fine sampling of conformations was restrained to be close to the starting conformation. A balance 
was achieved between extensive sampling and the speed required for screening a large compound 
library by fine sampling of side chain and ligand torsion angles only around their starting conformations, 
as illustrated by sticks in Figure 2C.
In the screening steps of computational docking (Figure 2A), a library of ∼18,000 purchasable 
compounds (Sets 1 and 2) was scanned computationally for structural compatibility with the pharma-
cophore (ligand binding site) presented by a single sheet of the Aβ16–21 steric zipper. Structural 
compatibility was assessed by a combination of binding energy (Meiler and Baker, 2006) and steric 
complementarity (Lawrence and Colman, 1993). After computational docking, the distribution of 
calculated binding energies suggests that, statistically the flat compounds from Set 2 fit more snugly 
on the flat surfaces of Aβ16–21 fibers than those with diverse shapes in Set 1 (Figure 2B). The best 
scoring compounds were screened further by requiring that each is also structurally compatible with 
the solid-state NMR-derived model of the Aβ full-length fiber structure (Petkova et al., 2006) (Figure 1C 
and Figure 1—figure supplement 3).
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Experimental characterization of BAFs
After in silico screening of a library of ∼18,000 purchasable compounds, twenty-five of the top-ranking 
compounds all with better scores for binding energy and steric complementarity than orange G 
(Figure 1D, Figure 2—figure supplement 1), were selected for experimental validation. First these 25 
compounds were tested for their ability to protect mammalian cells from Aβ toxicity (Figure 1E, Tables 1 
and 2), and five of them were found to reduce the toxic effects of Aβ. These five were tested for 
binding to both Aβ1–42 and Aβ16–21 fibers by NMR. Two were found to have tighter binding than orange 
G, and the others gave insufficient NMR signals for detection. To expand this set of the five compounds, a 
Figure 1. Structure-based identification of small compound inhibitors of Aβ toxicity. In step (A) the crystal structure (Landau et al., 2011) is determined of a 
complex of an amyloidogenic segment of Aβ (in this case residues 16-KLVFFA-21 of the spine of the Aβ fiber) with an amyloid-binding Ligand X (in this case 
orange G), revealing aspects of the pharmacophore for Ligand X. Prior to step (B) a large library of available compounds is selected for computational 
docking (∼18,000 purchasable compounds in this case). In step (B) computational docking is applied to test the compatibility of each member of the library 
for the pharmacophore of the amyloidogenic segment defined in step (A). In step (C), the top scoring members of the library are tested for compatibility of 
binding within a full-length Aβ fiber (in this case the 400 top scoring members were tested on a solid state NMR-derived model of an Aβ fiber, pdb entry 
2LMO) (Petkova et al., 2006). The representative models from steps B and C are shown in Figure 1—figure supplements 1 and 2. In step (D), the 
compounds are ranked by tightest binding energy and best shape complementarity for the pharmacophore. In step (E), the top-ranking compounds 
(25 in this case) are selected for experimental characterization and validation, including NMR assessment of binding, EM assays of their effects on fiber 
formation, and cell viability assays for their effects on Aβ cytotoxicity. In step (F), new compounds (9 in this case) and compound derivatives (17 in this 
case) are selected for an additional cycle of computational and experimental testing, based on their similarity to the lead compounds from the initial cycle.
DOI: 10.7554/eLife.00857.003
The following figure supplements are available for figure 1:
Figure supplement 1. Structural models of the representative BAFs and orange G docked to the side of the KLVFFA(Aβ16–21) fiber. 
DOI: 10.7554/eLife.00857.004
Figure supplement 2. Structural models of the representative BAFs and orange G docked onto the full-length Aβ fiber. 
DOI: 10.7554/eLife.00857.005
Figure supplement 3. Alternative binding modes of BAF1 with the Aβ full-length fibers. 
DOI: 10.7554/eLife.00857.006
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Figure 2. Computational screening for fiber-binding compounds. (A). Outline of our procedure for structure-based 
screening. We prepare two sets of compounds (shown in the upper left) for screening against both types of fibers 
shown in the upper right. Compound Set 1 is the intersection of the ZINC Database of purchasable compounds 
with the Cambridge structural database (CSD) of known structures. Set 2 consists of other flat aromatic and 
multiple conjugated compounds found in the ZINC Database. The full description of each computational step is in 
‘Materials and methods’. (B). Distribution of calculated binding energies for the compound libraries of Sets 1 and 2. 
Those top-ranking compounds have better predicted binding energy than orange G. Structural comparison of 
docked models of such compound BAF8 and orange-G is discussed in the Figure 2—figure supplement 1. 
Notice the starred bins which suggest that some members of Set 2, containing flat compounds, tend to be  
among the top scoring compounds, presumably having the tightest binding to the flat fiber surface. (C). The 
conformational ensemble of a compound representative shown docked onto the Aβ16–21 fiber structure. (D). A 
model of BAF8 docked onto an NMR-derived model of full-length Aβ fiber. Notice that the apolar ring structure of 
the compound binds to the relatively flat apolar (gray) surface of the fiber, and the polar moieties of the compound 
(red) form hydrogen bonds to the polar groups of the fiber (yellow). The stereo view of BAF8 model is shown in 
Figure 2—figure supplement 2.
DOI: 10.7554/eLife.00857.007
Figure 2. Continued on next page
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second cycle of inhibitor discovery was performed. From the computed positions of the five compounds, 
a refined pharmacophore was inferred (Figure 1F), and used in the next cycle of screening. Added to 
the compound set were nine additional compounds apparently related to the five lead compounds 
from the initial cycle, plus 17 chemical derivatives of compounds (Tables 1 and 3). The second cycle 
produced three additional compounds and three compound derivatives that also protected the 
mammalian cells from Aβ fibers. One of these compounds was confirmed by NMR to bind to Aβ fibers. 
The detailed description of those experimental results is as follows.
Inhibition of Aβ1–42 toxicity by BAFs
Having identified compounds that bind Aβ fibers, by a structure-based procedure, we tested their 
effects on the cytotoxicity of Aβ1–42 fiber against two mammalian cell lines: PC12 and HeLa (Figure 3). 
Five BAFs—1,4,8,11, and 12—in the initial cycle and three additional BAFs—26, 30, and 31—from the 
second cycle, with diversified chemical structures shown in Figure 4, significantly increased both PC12 
and HeLa cell survival after 24 hr incubation with Aβ1–42 (0.5 µM) at concentration of 2.5 µM, while the 
BAFs alone had little or no effect on cell survival (Figure 3—figure supplement 1). Three BAFs—11, 
26, and 31—showed clear dose-response profiles in their protection of both PC12 and HeLa cells 
(Figure 3B). Among them, the two best BAFs—26 and 31—were tested and did not affect the 
cytotoxicity of amyloid fibers other than Aβ (Figure 3—figure supplement 2). Although all of these BAFs 
provide protection against Aβ toxicity, none diminish the amount of Aβ fibers in electron micrographs 
(Figure 3C).
Validation of compound binding by NMR titration
Promising candidate binders from in silico screening and toxicity tests were validated by titration of Aβ 
fibers into solutions of each compound, as monitored by NMR signals of aromatic protons of the 
compound (Figure 5). The proton resonances of the freely rotating compounds disappear as the 
compound binds to the fibers. By increasing the amount of fibers, an apparent Kd for compound 
binding can be estimated. From in silico screening, all tested BAF compounds are calculated to bind 
more tightly to Aβ fibers than orange G. In NMR studies, the apparent Kd of orange G binding to 
Aβ16–21 fibers was found to be 43 ± 21 µM, whereas the apparent Kd of BAF1 binding to Aβ16–21 fibers 
is 12 ± 7 µM. BAFs were found to bind to both Aβ16–21 fibers and Aβ1–42 fibers. Figure 5F shows a notable 
correlation between the calculated binding energies and the reduction in NMR peak areas upon Aβ 
binding. That is, all BAFs with predicted binding energy better than orange G also reduce NMR peak 
areas more than orange G. On the other hand, BAF31ΔOH, a derivative of BAF31 by removal of a key 
hydroxyl group essential for binding, exhibits both a worse calculated binding energy and a diminished 
reduction of NMR peak upon titration of Aβ1–42 fibers.
Structure-activity relationship studies of the Aβ pharmacorphore
Based on the lead compounds found in the initial cycle of the procedure, we carried out a second cycle 
to expand our understanding of the Aβ pharmacorphore. BAF11 (Figure 6A), one of the lead compounds 
in the initial cycle, was used to perform structure-activity relationship studies. Twelve derivatives 
of BAF11 were scanned to pinpoint the essential apolar and polar interactions for the pharmacor-
phore refinement (Figure 6B, Figure 6—figure supplement 1). These derivatives are grouped in five 
classes, whose effects on Aβ toxicity have been tested (Figure 6C). Classes I and II assess the polar 
region of BAF11, which makes hydrogen bonds to charged Lys16 ladders of the Aβ fiber: the deletion 
of the hydroxyl group (Class I) significantly decreased the inhibition of toxicity; the swapping of 
the hydroxyl group with the aromatic tail (Class II) almost abolished inhibition of toxicity. Classes 
III, IV, and V focused on the aromatic moieties of BAF11: altering the sizes of aromatic groups 
(Class III) showed little change in inhibition of toxicity while adding charged or polar groups within 
The following figure supplements are available for figure 2:
Figure supplement 1. Structural comparison between docked models of BAF8 and orange G. 
DOI: 10.7554/eLife.00857.008
Figure supplement 2. Stereo view of the structural model of BAF8 with Aβ fiber. 
DOI: 10.7554/eLife.00857.009
Figure 2. Continued
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aromatic region (Classes IV and V) resulted in a significant decrease of inhibition of toxicity. These 
differences among BAF11 derivatives in inhibition of toxicity (Figure 6C) further validated our 
structure-based approach and provided guidelines for the refinement of Aβ pharmacophore.
Table 1. List of all tested BAF compounds
Compound
Molecular  
formula
Molecular  
weight*
Sources/ 
purchasing
Rescuing 
percentage (%) ZINC entry
BAF1 C20H8Br4O5 648 Sigma-Aldrich 44 ± 7 ZINC04261875
BAF2 C19H14O5S 354 Sigma-Aldrich 4 ± 3 ZINC03860918
BAF3 C16H13NO3 267 Ryan Scientific 4 ± 5 ZINC04289063
BAF4 C24H16N2O6 428 Aldrich 88 ± 22 ZINC13346907
BAF5 C16H7Na3O10S3 524 Sigma-Aldrich 11 ± 7 ZINC03594314
BAF6 C26H20N2 360 Alfa-Aesar 5 ± 7 ZINC08078162
BAF7 C18H12N6 312 Alfa-Aesar 2 ± 2 ZINC00039221
BAF8 C17H14N2O5S 358 Sigma-Aldrich 23 ± 11 ZINC12358966
BAF9 C19H13N3O4S 379 NCI plated 2007† −3 ± 22 ZINC03954432
BAF10 C17H13NO3 279 NCI plated 2007 3 ± 5 ZINC00105108
BAF11 C20H13N2O5S 393 NCI plated 2007 48 ± 12 ZINC04521479
BAF12 C13H8Br3NO 434 NCI plated 2007 38 ± 6 ZINC12428965
BAF13 C19H16ClNO4 358 Sigma-Aldrich 0 ± 2 ZINC00601283
BAF14 C10H6S2O8 318 Sigma-Aldrich 3 ± 3 ZINC01532215
BAF15 C23H28O8 432 Sigma-Aldrich 13 ± 4 ZINC00630328
BAF16 C19H19NO5 341 Sigma-Aldrich 5 ± 8 ZINC28616347
BAF17 C23H25N5O2 404 Sigma-Aldrich 6 ± 3 ZINC00579168
BAF18 C24H16O2 336 ChemDiv 6 ± 2 ZINC02168932
BAF19 C18H14N2O6 354 ChemDiv 3 ± 4 ZINC01507439
BAF20 C25H19N5OS 438 ChemDiv 8 ± 4 ZINC15859747
BAF21 C19H14Br2O 418 ChemDiv 6 ± 3 ZINC38206526
BAF22 C21H16N2O3S2 408 Life Chemicals 3 ± 5 ZINC04496365
BAF23 C16H11ClO5S 351 Enamine Ltd 3 ± 5 ZINC02649996
BAF24 C23H19NO3 357 Sigma-Aldrich 16 ± 5 ZINC03953119
BAF25 C14H8Cl2N4 303 Sigma-Aldrich 4 ± 3 ZINC00403224
BAF26 C17H10O4 278 Aldrich 46 ± 23 ZINC05770717
BAF27 C21H16BrN3O6 486 ChemBridge 4 ± 1 ZINC01208856
BAF28 C17H12N2O3 292 ChemBridge 2 ± 4 ZINC00061083
BAF29 C22H10N4O2 362 ChemBridge 1 ± 5 ZINC00639061
BAF30 C14H8O5 256 Aldrich 18 ± 13 ZINC03870461
BAF31 C19H21NO3 311 Sigma 84 ± 12 ZINC00011665
BAF32 C15H14O7 306 Sigma-Aldrich 15 ± 9 ZINC03870336
BAF33 C27H33N3O8 528 Sigma-Aldrich 7 ± 2 SIGMA-R2253§
BAF34 C30H16N4O14S4 785 Aldrich ‡ ALDRICH-S432830§
orange G C16H12N2O7S2 408 Sigma-Aldrich −2 ± 8 ZINC04261935
The 25 compounds (BAF1-25) are from the first round, and the nine compounds (BAF26-34) are from the second round. 
Another set of the 17 derivatives of the BAFs are shown in Table 3.
*Molecular weight (anhydrous basis) excluding the salt and water molecules.
†National Cancer Institute (NCI) free compound library (http://dtp.nci.nih.gov/).
‡Toxicity results of BAF34 were not consistent among several independent replica experiments, possibly due to 
impurity and the high molecular weight of the compound.
§ZINC entry of the compound is not applicable, and the catalog number from Sigma-Aldrich is provided.
DOI: 10.7554/eLife.00857.010
Biophysics and structural biology | Human biology and medicine
Jiang et al. eLife 2013;2:e00857. DOI: 10.7554/eLife.00857 8 of 27
Research article
In the second cycle, nine new compounds were derived from the refined pharmacophore (Figure 7). 
Three of them detoxified Aβ in cell survival assay. BAF31, the best inhibitor which protected mammalian 
cells from Aβ toxicity in the second cycle, increased cell survival from the 40% induced by Aβ alone to 
>90% (Figure 3). A derivative of BAF31, BAF31ΔOH, lacking the hydroxyl group believed to bind to 
the Lys residue of the Aβ fiber (shown by the magenta oval in Figure 8B), is calculated no longer to 
bind to the Aβ fiber. NMR and cell viability assessments indicated that BAF31ΔOH binds much less 
strongly to Aβ fibers than BAF31 itself and shows significantly reduced power to inhibit toxicity (Figure 8E). 
Similarly, the detoxifying profile of derivatives of another inhibitor, BAF30, validated the key interactions 
of BAF30 across the binding interface (Figure 9). Our conclusion is that the NMR binding and toxicity 
results for the BAF derivatives studied are consistent with our model for the pharmacophore of Aβ 
(Figure 10).
Discussion
Structure-based discovery of compounds that bind amyloid fibers
Amyloid fibers differ fundamentally in structure from the enzymes and signaling proteins that are the 
traditional targets in structure based design of binding compounds, and thus their pharmacophores 
might be expected to differ fundamentally as would the types of compounds that bind. In general, 
the binding sites of the traditional targets are often concave pockets; in contrast, the surfaces of 
amyloid fibers are flat and repetitive along the fiber axis, without well-defined surface cavities. The 
widely used ligand-docking software, such as DOCK (Ewing et al., 2001), or AutoDock (Morris 
et al., 2009), is intended to fit well-defined protein pockets rather than shallow grooves at flat fiber 
surfaces.
Consequently we have adapted the RosettaLigand program (Davis and Baker, 2009) for docking a 
library of commercially available compounds onto the flat surface of amyloid fibers. Similarly to other 
software packages, RosettaLigand scores each candidate compound for its energetic fit to its binding 
site. The initial site is chosen near that occupied by a bound compound, as determined in a crystal structure. 
The conformational flexibilities of ligand and protein side chains are modeled in a ‘near-native’ perturbation 
Table 2. Detailed list of the active BAF compounds
Compound
Molecular  
formula
Molecular  
weight*
Sources/ 
companies Purity
Rescuing 
percentage§ 
(%) ZINC entry  
code¶ SMILES stringPC12 Hela
BAF1 C20H8Br4O5 647.9 Sigma-Aldrich ∼99% 38 ± 11 44 ± 7 ZINC04261875 c1ccc2c(c1)C(=O) 
OC23c4ccc(c(c4Oc5c3ccc(c5Br)O)Br)O
BAF4 C24H16N2O6 428.4 Aldrich ≥95% 85 ± 18 88 ± 22 ZINC13346907 c1cc(c(cc1O)O)c2cc3c(cc2N)oc-4cc(=O) 
c(cc4n3)c5ccc(cc5O)O
BAF8 C17H14N2O5S 358.4 Sigma-Aldrich ≥90% 26 ± 12 23 ± 11 ZINC12358966 Cc1ccc(c(c1)/N=N/c2c3ccccc3c(cc2O) 
S(=O)(=O)[O-])O
BAF11 C20H13N2O5S 393.5 NCI plated 2007 † 51 ± 11 48 ± 12 ZINC04521479 c1ccc2c(c1)ccc(c2O)/N=N/c3c4ccccc4c(cc3O) 
S(=O)(=O)[O-]
BAF12 C13H8Br3NO 433.9 NCI plated 2007 † 19 ± 6 38 ± 6 ZINC12428965 c1cc(ccc1/N=C/c2cc(cc(c2O)Br)Br)Br
BAF26 C17H10O4 278.3 Aldrich ‡ 60 ± 21 46 ± 23 ZINC05770717 c12c(cc(cc1)C(=O)C=O)Cc1c2ccc(c1) 
C(=O)C=O
BAF30 C14H8O5 256.2 Aldrich ‡ 37 ± 18 18 ± 13 ZINC03870461 c1cc2c(cc1O)C(=O)c3c(ccc(c3O)O)C2=O
BAF31 C19H21NO3 311.4 Sigma ≥98% 92 ± 22 84 ± 12 ZINC03874841 CCCN1CCC2=C3C1CC4=C(C3=CC(=C2)O) 
C(=C(C=C4)O)O
BAFs 1, 4, 8, 11, 12 are from the first round. BAFs 26, 30, 31 are from the second round.
*Molecular weight (anhydrous basis) excluding the salt and water molecules.
†With the standard of NCI free compound library.
‡Analytical data for AldrichCPR products are not available.
§Rescue percentage is a scaled cell survival rate.
¶Entry code for the ZINC database (http://zinc.docking.org).
DOI: 10.7554/eLife.00857.011
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fashion (‘Materials and methods’), meaning that the fine sampling of conformations was restrained to be 
close to the starting conformation. To find the position along the flat fibrillar surface of greatest binding 
energy for each candidate compound, our screening approach leverages the rotamer repacking algorithm 
(Leaver-Fay et al., 2011) and Rosetta energy function (Kuhlman and Baker, 2000) to account for 
Table 3. List of the representative BAFs 11, 30, 31 and their derivatives
Compound
Molecular  
formula
Molecular  
weight Description
Toxicity  
inhibition (%)
ZINC entry/
catalog no.
BAF31 C19H21NO3 311 84 ± 12 ZINC03874841
 BAF31ΔOH C19H21NO2 295 remove one  
hydroxyl (OH)
15 ± 2 ZINC03874841
BAF30 C14H8O5 256 18 ± 13 ZINC03870461
 BAF30αR C22H20O13 492 add additional  
R group away from  
binding interface
20 ± 10 ZINC28095922
 BAF30σOHAαOH C14H8O6 272 change one OH (A)  
position; add  
another OH
9 ± 9 ZINC03874832
BAF30σOHAΔOHBαCOO C15H8O6 284 move one OH (A)  
position; delete  
an OH from loc B;  
add a carboxyl
9 ± 3 ZINC04098704
 BAF30σOHABαCH3 C15H10O5 270 move two OH (AB)  
positions; add a 
methyl
6 ± 3 ZINC03824868
BAF11 C20H13N2O5S 393 48 ± 12 ZINC04521479
 BAF11ISO C20H13N2O5S 393 isomer form  
of BAF11
33 ± 5 ZINC12405071
 BAF11σR1 C20H14N4O8S2 502 change the  
aromatic group
35 ± 9 ZINC25558261
 BAF11σR2 (BAF8) C17H14N2O5S 358 change the  
aromatic group
22 ± 11 ZINC12358966
 BAF11σR3 C16H12N2O6S 360 change the  
aromatic group
28 ± 4 ZINC04900892
 BAF11αNO2- C20H12N3O7S 438 add charged  
group (nitro)
15 ± 6 ZINC16218542
 BAF11ISOαCOO- C21H12N2O7S 436 BAF11 isomer;  
add charged  
group (carboxyl)
6 ± 5 ZINC03861030
 BAF11ISOαSO3- C20H11N2O11S3 552 BAF11 isomer;  
add charged  
group (sulfate)
2 ± 5 SIGMA-33936
 BAF11ΔOHσR C20H14N2O4S 378 remove an OH; 
change the position  
of the aromatic group
15 ± 6 ZINC04803992
 BAF11ΔOHαSO3- C20H14N2O7S2 458 remove an OH;  
add sulfate group
12 ± 3 ZINC03954029
 BAF11ΔOHαR C20H18N4O5S 426 remove an OH;  
add additional  
group to the  
aromatic ring
12 ± 6 ZINC04416667
 BAF11σOHαR1 C24H20N4O4S 461 swap the position  
of the OH and  
aromatics
5 ± 5 ZINC04804174
 BAF11σOHαR2 C16H19N3O5S 365 swap the position  
of the OH and  
aromatics
4 ± 6 ZINC17378758
DOI: 10.7554/eLife.00857.012
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flexibility of protein side chains and ligand, which is critical in modeling of such shallow grooves on the 
fiber surface.
Our procedure identified 34 BAF compounds predicted to bind to Aβ fibers, among which eight 
BAFs diminish the toxicity of the fibers in mammalian cells. We suggest that the same procedure can 
be used to discover other compounds that reduce the toxicity of Aβ fibers, starting from other co-crystal 
structures of Aβ segments with other bound ligands. Similarly, the same procedure can be applied to 
the discovery of compounds that bind to other amyloid proteins, for use as either toxicity inhibitors or 
imaging agents for amyloid diagnosis.
Mechanism of inhibition of Aβ toxicity
Our observation is that our tightest binding BAFs all diminish the toxicity of Aβ fibers, and yet 
do not substantially diminish the amount of fibers. Further study will be required to understand 
the molecular mechanism underlying the inhibition of Aβ toxicity, but here we offer the following 
hypothesis.
Figure 3. Experimental characterization of compounds that bind to amyloid fibers. Our newly discovered BAFs 
diminish Aβ1–42 toxicity without significantly reducing Aβ1–42 fibrillation. (A). Eight BAFs reduce Aβ toxicity in 
mammalian cell lines (PC12 in orange; HeLa in green). These identified compounds with diversified chemical 
structures are quite different from orange G, whose co-crystal structure with an amyloid segment is the basis of our 
approach (Figure 4 and Table 2). For each compound, 2 to 4 repeats of each independent experiment were 
performed. For each experimental repeat, four replicates per sample per concentration were tested. The symbol * 
indicates a p<0.1; the symbol ** indicates a p<0.01 and the symbol *** indicates a p<0.001. The student’s t-test and 
p-value analysis are in Table 4. (B). The representative BAFs—31, 26, and 11—inhibit Aβ cyto-toxicity in a dose-
dependent manner. (C). Transmission electron microscopy (TEM) images of Aβ fibers alone and Aβ fibers with the 
BAFs, the same samples prepared for cell viability assay. All 8 BAFs that diminish Aβ toxicity do not noticeably 
diminish Aβ fibrillation. Scale bars indicate 200 nm.
DOI: 10.7554/eLife.00857.013
The following figure supplements are available for figure 3:
Figure supplement 1. The BAFs alone exhibit little or no toxicity on mammalian cell lines. 
DOI: 10.7554/eLife.00857.014
Figure supplement 2. BAFs cannot reduce the cytotoxicity of amyloid fibers formed by IAPP and α-synuclein, as 
much as those fibers formed by Aβ. 
DOI: 10.7554/eLife.00857.015
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Table 4. Student’s t-test and p value analysis suggests that BAFs reduce the cytotoxicity of Aβ fibers 
significantly
Average of cell  
viability (n = 4) SD(σ)
Comparison to  
Aβ fiber alone
t value p value
HeLa cell line
 Aβ fiber alone 0.40 0.05 / /
  BAF1 0.66 0.04 8.4 5E-05
  BAF4 0.93 0.13 7.4 1E-4
  BAF8 0.54 0.06 3.3 1E-2
  BAF11 0.69 0.07 6.6 2E-04
  BAF12 0.63 0.04 7.6 1E-04
  BAF26 0.68 0.14 3.8 5E-3
  BAF30 0.51 0.08 2.3 4E-2
  BAF31 0.91 0.07 11.5 7E-06
PC12 cell line
 Aβ fiber alone 0.37 0.07 / /
  BAF1 0.61 0.07 4.9 1E-3
  BAF4 0.90 0.11 8.0 7E-05
  BAF8 0.53 0.07 3.2 1E-2
  BAF11 0.69 0.07 6.5 2E-4
  BAF12 0.49 0.04 2.9 2E-2
  BAF26 0.74 0.13 5.0 1E-3
  BAF30 0.60 0.11 3.5 8E-3
  BAF31 0.95 0.14 7.4 1E-4
The Student’s T-test and p-value are based on the comparison to Aβ fiber alone.
DOI: 10.7554/eLife.00857.016
Emerging evidence suggests that amyloid oligomers, rather than amyloid fibers, are toxic 
entities (Hartley et al., 1999; Cleary et al., 2005; Silveira et al., 2005), and that perhaps toxic 
oligomers can be released from amyloid fibers (Xue et al., 2009; Cremades et al., 2012; Krishnan 
et al., 2012; Shahnawaz and Soto, 2012). By binding to fibers, BAFs stabilize them, thereby 
shifting the equilibrium of Aβ molecules from smaller, toxic entities towards the fibrillar state. The 
BAF compounds in their computationally docked sites on Aβ fibers contact several (as few as three 
and as many as six) adjacent β-strands of the fiber. By creating a low energy binding interface 
across several fiber strands, the BAFs apparently stabilize the Aβ fibers from breaking into smaller 
entities.
From previous studies, we expect BAFs to bind to amyloid fibers rather than oligomers. In recent 
work (Laganowsky et al., 2012; Liu et al., 2012), we proposed that amyloid forming proteins can 
enter either of two distinct aggregation pathways, which are separated by an energy barrier. One 
pathway leads to in-register fibers in which every β-strand lies directly above or below an identical 
strand in the fiber. The other pathway leads to out-of-register oligomers in which antiparallel β-strands 
are sheared relative to one another and roll into a β-barrel. We found that three out-of-register amyloid-
like structures exhibit cytotoxicity (Laganowsky et al., 2012; Liu et al., 2012), which tend to be 
transient, equilibrating eventually into in-register fibers. In our approach, we search for BAFs based on 
in-register β-sheets rather than out-of-register β-strands found in toxic oligomeric structures, to which 
our BAFs are not expected to bind (Figure 11). We speculate that BAFs stabilize the in-register fibers 
revealed by our steric zippers, relative to out-of-register toxic oligomers, thereby shifting the equilibrium 
from toxic oligomers towards fibers (Figure 12). Supporting this is our result that diminished toxicity 
accompanies compound binding.
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BAFs strengthen the hypothesis that Aβ16–21 fibers reflect essential 
features of full Aβ fibers
The identification of BAFs starts with the atomic structure of orange G bound within the fiber-like crystals 
of Aβ16–21, because as yet there is no high-resolution atomic structure available for ligands bound to full-
length Aβ fibers. Nevertheless, we found that BAFs diminish toxicity of full-length Aβ fibers. This finding 
suggests that the steric zipper structure of Aβ16–21 fibers recapitulates some of the essential structural 
features of full-length Aβ fibers. We are currently attempting cocrystallization of BAFs with Aβ16–21 and 
other steric zipper structures. We speculate that coupled with computational methods, other steric zipper 
structures could enable the discovery of the lead compounds for inhibitors of other toxic amyloid entities.
Materials and methods
Computational procedures
Two choices of compound libraries for structure-based screening
We generated two sets of purchasable compounds to be screened via the computational docking:
 
1. Cambridge Structure Database (CSD) set. 102,236 organic compounds, whose crystal structures 
have R-factor better than 0.1, were extracted from the Cambridge Structure Database (version 5.32 
November 2010) using ConQuest. The SMILES string of each structure was then used to locate its 
purchasing information among the ZINC purchasable set (http://zinc.docking.org/) (Irwin and 
Shoichet, 2005) by OpenBabel package (http://openbabel.org/) (Guha et al., 2006). The fast index 
table of all SMILES strings of the ZINC purchasable set was generated to allow the fast search of 
each CSD structure against ZINC purchasable set. CSD structures that failed in locating their 
purchasing information (i.e., without any hit in searching against ZINC purchasable set) were omitted. 
A library of 13,918 structures from CSD representing 11,057 compounds were finally compiled, 
whose purchasing information is annotated by ZINC purchasable database. The complete list of 
CSD/ZINC entries of these compounds in this CSD set can be found in Supplementary file 1.
2. Flat Compound (FC) set. A library of 6589 compounds containing phenol and less than three freely 
rotatable bonds were extracted from the ZINC database (http://zinc.docking.org/) (Irwin and Shoichet, 
2005). Those compounds have a common feature of planar aromatic ring, resulting in a ‘flat’ compound. 
Figure 4. Diversified chemical structures of 8 active BAF compounds that reduce Aβ toxicity. Orange G in an 
orange box is also displayed for comparison.
DOI: 10.7554/eLife.00857.017
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Figure 5. NMR evidence for binding of compounds to both Aβ16–21 and Aβ1–42 fibers. NMR binding experiments were performed on BAF compounds 
and the dye orange G. By monitoring the aromatic regions of the 1H NMR spectra of BAFs 1, 8, and 31, these compounds were shown to bind to both 
Aβ16–21 and Aβ1–42 fibers more tightly than does orange G. As shown in (A and B), BAF1 binds to Aβ16–21 fibers with affinity stronger than orange G. The 
determination of binding parameters for Aβ16–21 fibers is detailed in Table 5 and Figure 5—figure supplements 1 and 3. In panel (A), the 1H NMR 
spectrum of compound BAF1 (at 100 μM) is shown as a function of increasing concentration of Aβ16–21 fibers (0–500 μM, as monomer). The insert shows 
the area decrease of BAF1 NMR peaks as a function of Aβ16–21 concentration, and the red curve fitting the data defines an apparent Kd of 12 ± 7 µM. In 
panel (B), the NMR spectrum of orange G (50 μM) is plotted against increasing concentration of Aβ16–21 fibers (0–950 μM), giving an apparent Kd of 43 ± 21 µM. 
In (C, D and E), BAFs 1 and 8 both bind to Aβ1–42 fibers more strongly than orange G. Notice that the molar ratio of BAFs to Aβ1–42 fibers is comparable to 
that used in cell toxicity assays (Figure 3). (F). The calculated binding energies of BAFs—1, 8, and 31—to Aβ1–42 fibers are compared to the decreases in 
NMR peak of these compounds upon their binding to full-length Aβ fibers. These three BAFs have higher affinities and a larger NMR peak reduction 
than orange G while the ‘knock-out’ derivative with removal of key interactions (BAF31ΔOH) discussed below has a weaker calculated affinity and a 
smaller NMR peak reduction than orange G. We observe good correlation between computed energies and experimental data from NMR.
DOI: 10.7554/eLife.00857.018
The following figure supplements are available for figure 5:
Figure supplement 1. NMR peak assignment of BAF1 with Aβ16–21 fiber. 
DOI: 10.7554/eLife.00857.019
Figure supplement 2. NMR peak assignment of the control compound orange G with Aβ16–21 fiber. 
DOI: 10.7554/eLife.00857.020
Figure supplement 3. NMR titration of BAF8 with Aβ16–21 fibers. 
DOI: 10.7554/eLife.00857.021
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The flat compound library includes compounds with similar chemical structures to naturally fiber-
binding molecules, for instance, Thioflavin-T (ThT), Congo red, Green tea epigallocatechin-3-gallate 
(EGCG), and Curcumin. It also includes many natural phenols, such as gallic acid, ferulic acid, coumaric 
acid, propyl gallate, epicatechin, epigallocatechin, etc. The complete list of ZINC entries of these 
compounds in this FC set can be found in Supplementary file 2.
 
Ligand ensemble preparation with near-‘native’ perturbation
Each molecule in our two compound libraries was prepared for the docking simulations. Hydrogen 
atoms of each molecule were added for the compounds lacking modeled hydrogens using the 
program Omega (v. 2.3.2, OpenEye) (Bostrom et al., 2003). Ligand atoms were represented by the 
most similar Rosetta atom type, their coordinates were re-centered to the origin, and their partial 
charges were assigned by OpenEye’s AM1-BCC implementation. We then generated the ligand 
perturbation ensemble near the crystal conformation (CSD set) or starting conformation (FC set) of 
each molecule. For each rotatable bond of the ligand, a small degree torsion angle deviation (±5°) 
was applied. K-mean clustering method was used to generate the ligand perturbation ensemble 
and similar/redundant conformations (rmsd to the selected conformation is less than 0.5 Å) were 
omitted. Finally, up to 100 conformations for each ligand were generated and made available for 
Rosetta LigandDock.
Rosetta LigandDock with additional near ‘native’ perturbation sampling
We adopted the docking algorithm based on the method previously described in the RosettaLigand 
docking paper (Meiler and Baker, 2006; Davis and Baker, 2009). In general, the algorithm includes 
three stages: coarse-grained stage, Monte Carlo minimization (MCM) stage and gradient-based 
minimization stage. Whereas the original RosettaLigand method performed a full sampling of torsional 
degrees of freedom in the internal ligands and protein side-chains, we made modifications to enable 
Table 5. Predicted binding energy and experimental measurement of the binding of two BAFs and 
orange G against both Aβ16–21 (KLVFFA) and full-length Aβ fibers
Binding to KLVFFA fiber Binding to Aβ fiber
Predicted binding  
energy (kcal/mol)
NMR Kd  
(µM)
Predicted binding  
energy (kcal/mol)
NMR peak  
reduction (%)
BAF1 −8 12 −10 8
BAF8 −12 24 −12 13
orange G −8 43 −9 6
The determination of the binding parameters with KLVFFA fiber is detailed in Table 6.
DOI: 10.7554/eLife.00857.022
Table 6. Comparison of the measured binding parameters of the representative BAFs with orange G 
by NMR titrations
Compound Predicted binding energy (kcal/mol) fmax Kd (µM)
BAF1 −8 0.47 ± 0.04 12 ± 7
BAF8 −12 0.82 ± 0.04 24 ± 5
Orange-G −8 0.46 ± 0.06 43 ± 21
The second column lists the predicted binding energy for each top docked model of BAF compounds with KLVFFA 
fiber, and the binding energy of Orange-G with KLVFFA fiber were also calculated for comparison. Our 
computational method identified the BAF with better fit to the binding interface than Orange-G. We then used 
NMR titration to determine the binding affinity. Our previous mass spectrometric analyses of the crystal of the 
Orange-G with KLVFFA fibers have suggested a binding ratio of compound:fiber with the range of 1:1 to 1:10 
(Landau et al., 2011). Together with our structural models and single binding site assumption, we estimated the 
binding ratio to be 1:3. Accordingly, calculated NMR binding parameters are listed in the table. The third column 
fmax is the maximum fraction of NMR signal decrease of compound upon binding saturation (‘Materials and 
methods’).
DOI: 10.7554/eLife.00857.023
Biophysics and structural biology | Human biology and medicine
Jiang et al. eLife 2013;2:e00857. DOI: 10.7554/eLife.00857 15 of 27
Research article
the fast run time required by the screening method. Specially, we sampled the ligand and protein 
side-chain torsion angles in near-‘native’ perturbation fashion, where only the near-‘native’ conformation 
of side-chain and ligand rotamers were allowed and any conformation far away from the starting 
conformation was omitted. For each protein side-chain, the deviations (±0.33, 0.67, 1 SD) around each 
input torsion were applied based on the standard deviation value of the same torsion bin from the 
backbone-dependent Dunbrack rotamer library. For each internal torsional angle of the ligand, the 
deviations (±5°) around the input torsion were applied as described above.
Figure 6. Refinement of the Aβ pharmacorphore based on studies of BAF11. (A) Atomic model of BAF11 from the 
initial cycle docked on the full-length Aβ fiber, viewed in perpendicular to the fiber axis (left panel) and down the 
fiber axis (right panel). BAF11 is shown as a cyan stick model, whose polar groups form hydrogen bonds (green 
thick lines) to Lys16 of Aβ. The extensive non-polar interactions arise from the flat aromatic rings of BAF11 packing 
against the hydrophobic surface formed by Val18 and Phe20 of Aβ. (B) Schematic representation of the polar and 
nonpolar interactions of BAF11 and its derivatives modeled on the Aβ fiber (in orange and light brown). In the 
process of the Aβ pharmacophore refinement, five different classes (I–V) of BAF11 derivatives were introduced into 
the second cycle of screening, to expand the BAF set and to assess the specificity of the compounds identified in 
the initial cycle. The full description and chemical structure of each derivative are in Table 3 and Figure 5—figure 
supplement 1. (C) Comparison of the toxicity inhibition (defined in ‘Materials and methods’) among five types of 
BAF11 derivatives after 24 hr incubation with Aβ (0.5 µM). Notice that all changes to BAF11 which remove binding 
groups diminish its effectiveness as an inhibitor of toxicity.
DOI: 10.7554/eLife.00857.024
The following figure supplements are available for figure 6:
Figure supplement 1. Chemical structures of the lead compound BAF11 and its derivatives. 
DOI: 10.7554/eLife.00857.025
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To optimize possible interactions (H-bonding or packing) between compound and fiber, we carried 
out random perturbations to the TS rigid-body degrees of freedom (5 Å for translational degrees of 
freedom; 360° for full rotational degrees of freedom) to explore different rigid body arrangements. 
For each rigid-body perturbation, different conformations of fiber sidechains, and compounds were 
explored to maximize the binding interactions. We next carried out simultaneous quasi-Newton 
optimization of the compound rigid body orientation and the sidechain torsion angles, and in some 
cases, the torsion angles of the compound and the backbone torsion angles in the binding site, using 
the complete Rosetta energy function.
Docking of molecules to KLVFFA and Aβ fibrillar structure
The structure of KLVFFA fiber was taken from the co-crystal structure of KLVFFA with orange 
G (pdb entry: 3OVJ) (Landau et al., 2011). After removing orange G, the sidechain torsion of 
KLVFFA was optimized to correct any conformational bias from the presence of orange G, and 
then the optimized structure were inspected to ensure that sidechain torsions are still within the 
original conformation of the co-crystal structure. The Aβ fibrillar structure was from ssNMR fiber 
structure of full-length Aβ (pdb entry: 2LMO) 40. The same optimization step was applied before 
docking. The comparison of docking onto both KLVFFA and Aβ fibrillar structure are discussed in 
Figure 13.
Post-docking analysis to rank the compounds
The docked compounds were filtered based on the following criteria: (1) The docking models with a 
compound-fiber van der Waals attractive energy > −7.0 kcal/mol were removed; (2) The docking 
models with a compound-fiber hydrogen-binding energy >−0.2 kcal/mol were eliminated. The 
remaining docked compounds were then ranked according to the energy of binding of compound to 
fiber. We used not only the total binding energy but also on each of the energy components separately 
(Lennard-Jones interactions, solvation, hydrogen bonding, and electrostatics) (Lazaridis and Karplus, 
1999; Kuhlman and Baker, 2000; Kortemme et al., 2003) for ranking. The compounds ranked in the 
top 40% according to all of these measures were selected. Finally, the compounds were ranked by 
tightest binding energy (Meiler and Baker, 2006) and best shape complementarity (Lawrence and 
Colman, 1993).
Figure 7. New BAFs derived from the refined amyloid pharmacophore. (A). Amyloid pharmacophore based on 
the structural overlay of active BAFs and derivatives. The overlay of the lead compounds from the initial round 
(BAF4, BAF8, and BAF11) elucidated the consensus of polar and nonpolar interactions at fiber binding  
interfaces, which sheds light on the amyloid pharmacophore. The amyloid pharmacophore was further refined  
by iterative approaches of computational docking and experimental testing. The derivatives of those lead 
compounds were tested to explore the essential role of those consensus interactions, and the differences of 
binding patterns and toxicity inhibition effects of the BAF derivatives can provide a guideline for the further 
refinement of amyloid pharmacophore. (B). New BAFs were ‘designed’ based on the refined pharmacophore. 
One successful example, BAF31 (green sticks) derived from the pharmacophore (grey sticks), showed the 
enhanced capability of inhibiting Aβ toxicity (Figure 8C). The success of developing enhanced binder from 
pre-defined pharmacophore highlights the important role of iterative docking/test approach in structure-based 
drug development.
DOI: 10.7554/eLife.00857.026
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Description of geometrical parameters of the interactions between 
BAFs and Aβ fiber defined based on structure-based screening of Aβ 
toxicity inhibitor
Based on the rounds of computing search and experimental test, general rules of the essential interac-
tions of BAF binding to Aβ fibers are summarized here. As illustrated in Figure 10, the geometrical 
parameters of those key interactions are specified as followings: 
Figure 8. Elimination of one key hydrogen bond from BAF31 causes both the loss of NMR binding to Aβ fibers and 
the decrease in inhibition of Aβ cyto-toxicity. (A) Atomic model of the new inhibitor BAF31 (our most tightly binding 
BAF) derived from the refined pharmacophore (Figure 7, Figure 1F) in the second cycle, viewed perpendicular to the 
fiber axis on the left and down the fiber axis on the right. In panel (B), one important hydroxyl group forming 
hydrogen bonds to Lys16 residue of Aβ is highlighted by a magenta circle. (C) A representative NMR band (left panel) 
of mixture of Aβ fiber with the compound BAF31 compares with that (right panel) of Aβ fiber the derivative BAF31ΔOH 
which omits that important hydroxyl group. Their full NMR spectrums showing the same trend are shown in 
Figure 8—figure supplement 1. (D) Cell survival rates after 24 hr incubation with Aβ (0.5 µM), the molar ratio (1:5) 
of Aβ and the compound is comparable with the ratio in NMR binding experiment (C). (E) Notably, the elimination 
of one hydrogen bond from BAF31 (the derivative BAF31ΔOH) causes both the marked decrease in inhibition of 
Aβ toxicity to HeLa cells (D) and the loss of NMR binding to Aβ fibers (C).
DOI: 10.7554/eLife.00857.027
The following figure supplements are available for figure 8:
Figure supplement 1. NMR titration of BAF31 and its derivative with the Aβ1–42 fiber. 
DOI: 10.7554/eLife.00857.028
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1. H-bond acceptor (or negative charge) of the inhibitor makes either hydrogen bond or salt bridge 
to sidechain nitrogen atoms (NZ) of at least two Lysine residues from adjacent Aβ strands along the 
fiber axis. Our data suggest that the BAFs need to have good contacts across 2 to 4 adjacent Aβ 
strands, in order to effectively bind to Aβ fiber and reduce Aβ toxicity.
Figure 9. Analysis of the lead compound BAF30 and its derivatives. Structural models of BAF30 (green sticks) 
docked on Aβ fiber structure (in a light yellow color) are shown in (A and B). The important polar (black hydrogen 
bonds) interaction between BAF30 and single β-sheet of Aβ fiber, as well as shape complimentary between the 
aromatic rings of BAF30 and the hydrophobic patches of Aβ fiber are highlighted respectively. Schematic 
representation of the polar and nonpolar interactions of BAF30 with Aβ fiber is shown in panel (C). The magenta 
circles highlight two important hydroxyl groups which are absent in BAF30 derivatives. (D). The chemical 
structure of each derivative is listed. The dark blue open circles indicate the deletion of the important hydroxyl 
group. The red color in chemical structures indicates the addition of atoms or groups to BAF30. (E). HeLa cell 
survival rates in the presence of Aβ (0.5 µM monomer equivalent) and BAF30 or the derivatives are compared. 
The hydrogen bonds between BAF30 and Lys16 residues of Aβ fiber are important for binding of Aβ fiber and 
inhibition of Aβ toxicity. With additional groups at the opposite side of hydrogen binding sites, the derivative 
BAF30αR showed little change in toxicity inhibition. However, two BAF30 derivatives (σOHAαOH and 
σOHAΔOHBαCOO), which alter or delete the two important hydroxyl groups (magenta circles in panel C) of 
BAF30 that form hydrogen bonds to Lys16, showed a significant decrease in the toxicity inhibition. Furthermore, 
when BAF30 was modified by shifting both hydroxyl groups (A and B) to their neighboring positions, the 
derivative BAF30σOHABαCH3 almost lost the inhibition of Aβ toxicity. The rescuing percentage (%) is defined in 
‘Materials and methods’.
DOI: 10.7554/eLife.00857.029
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2. The hydrogen bond or salt bridge described in 1) follows the general rule of H-bond geometry, 
which are:
 
A. Distance (d1, as shown in the figure) between the NZ atom of Lys16 and H-bond acceptor atoms 
of BAFs: 2.8∼3.5 angstrom;
B. Angle (Θ1) at BAF H-bond acceptor atoms:100∼150°;
C. Angle (Θ2) at the NZ atom of Lys16: 130∼180°. 
3. Hydrophobic interactions between the apolar residues (phenylalanine18 and valine 20) and the 
planar aromatic portion of the compounds. The aromatic portion of compounds should be planar 
or semi-planar to pack against the flat surface of Aβ which spans across at least two adjacent Aβ 
strands.
4. The hydrophobic interactions described in 3) follow the pi-pi stacking geometry, which are:
 
A. Distance (d2) between the center of the apolar sidechains and the center of BAF aromatic rings: 
4.0∼5.0 angstrom;
B. Dihedral angle (Φ) between the surface plane defined by Phe18 and Val20 and the aromatic ring 
of the BAFs: 0∼40°. 
Figure 10. General rule of the essential interactions between BAFs and Aβ fiber can be derived from structure-based 
screening of Aβ toxicity inhibitor. The carbonyl group is used to represent the H-bond acceptor (or negative charge) 
of BAFs, and the naphthalene ring is used to represent the planar aromatic portion of BAFs. Based on the rounds 
of computing search and experimental test, the detailed description about essential interactions and geometrical 
parameters are in ‘Materials and methods’.
DOI: 10.7554/eLife.00857.030
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Experimental procedures
Chemicals and reagents
Chemicals were obtained from a variety of companies (Table 1) and were of the highest purity available.
Source of KLVFFA(Aβ16–21) and Aβ1–42 peptide
N-terminal acetylated and C-terminal amidated KLVFFA(Aβ16–21) peptide was synthesized by Celtek 
Bioscience Peptides (Nashville, TN). Aβ1–42 peptide was overexpressed through Escherichia coli recom-
binant expression system and was purified as reported previously (Finder et al., 2010). The fusion 
construct for Aβ1–42 expression contains an N-terminal His tags, followed by 19 repeats of Asn-Ala-Asn-Pro, 
TEV protease site and the human Aβ1–42 sequence. Briefly, the fusion construct was expressed into 
inclusion bodies in E.coli BL21(DE3) cells. 8 M urea was used to solubilize the inclusion bodies. Fusion 
proteins were purified through HisTrap HP Columns, followed by Reversed-phase high-performance 
liquid chromatography (RP-HPLC). After TEV cleavage, Aβ1–42 peptide was purified from the cleavage 
solution by RP–HPLC followed by lyophilization. To disrupt preformed aggregation, lyophilized Aβ1–42 
was resuspended in 100% Hexafluoroisopropanol (HFIP) which was finally removed by evaporation.
Preparation of KLVFFA (Aβ16–21) and Aβ1–42 fiber samples for 1D 1H NMR 
titration measurement
KLVFFA (Aβ16–21) peptide was dissolved in PBS buffer, pH 7.4 at the concentration of 1 mM and incubated 
at 37° with continuing shaking for 3 months. Pre-disaggregated Aβ1–42 was dissolved in PBS buffer, pH 7.4 at 
the concentration of 200 μM and incubated at 37° with continuing shaking for 2 months. For NMR titration 
Figure 11. BAFs are designed to bind to in-register β-sheets, rather than out-of-register β-sheets. As illustrated in (A), 
BAFs bind to in-register β-sheets. Our structure-based approach searches for BAFs based on in-register β-sheets in Aβ 
fibers. These BAFs are predicted to bind along the flat hydrophobic surfaces of the fibers and are anchored by polar 
sidechains of Lysine residues. The Cβ distances between the Lys residues interacting with the BAFs are ∼9.6 Å following 
the stacked arrangement of in-register β-sheets. Orange G, as well as screened BAFs, favorably interact with the 
in-register fiber and are compatible with the geometry of the Lys residues aligned in in-register β-sheets. As illustrated in 
(B), BAFs cannot bind to out-of-register β-sheets. The estimation of Cβ distance between the lysine residues, based on 
three out-of-register β-sheets structures previously determined (Laganowsky et al., 2012; Liu et al., 2012), ranges from 
11 Å to 14 Å, quite different from the ∼9.6 Å measured in in-register β-sheet. We speculate that the BAFs are unable to 
bind to out-of-register β-sheets, and this difference accounts for the diminished toxicity that accompanies compound 
binding. Supporting this is our in vitro cell toxicity tests (Table 7 and Figure 11—figure supplement 1).
DOI: 10.7554/eLife.00857.031
The following figure supplements are available for figure 11:
Figure supplement 1. Active BAFs show no or little effects on the cyto-toxicity of pre-formed Aβ oligomers. 
DOI: 10.7554/eLife.00857.032
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samples preparation, KLVFFA (Aβ16–21) or Aβ1–42 fiber stocks were diluted in the PBS buffer solution at the 
indicated concentrations, followed by adding the small molecules from 100 mM stock solutions in DMSO 
into fibrillar solution. The final concentration of the small molecule was 50uM or 100 μM. The final volume 
of NMR samples was 500 μL containing 5% D2O. Prior to NMR spectra collection, samples were incubated 
at room temperature for 0.5 hr. 500 MHz 1H NMR spectra were collected on a Bruker DRX500 at 283 K with 
either 256 or 1024 scans collected depending on the intensity of the small molecule signal. H2O resonance 
was suppressed via excitation sculpting (Hwang and Shaka, 1995); DMSO resonance was suppressed 
via a frequency shifted presaturation of the DMSO peak. Spectra were processed with XWINNMR 3.6.
Dissociation constant (Kd) of small molecules to fibers calculated from  
NMR data
NMR data were analyzed to estimate the binding constant for the interaction between the BAF 
compounds and KLVFFA fibers. We monitored the decrease in the 1H aromatic resonance of the 
Table 7. BAFs reduce Aβ cyto-toxicity by targeting fibers rather than oligomers.
Compound
Inhibition to the cyto-toxicity  
of Abeta oligomers (%)
Inhibition to the cyto-toxicity 
of Abeta fibers (%)
BAF1 −4 ± 6 36 ± 9
BAF11 −9 ± 7 7 ± 7
BAF26 −6 ± 6 26 ± 7
BAF31 −17 ± 15 58 ± 7
The BAF inhibitions of toxicity from either Aβ oligomer or fibers are compared. Four BAFs, which reduce the toxicity of 
Aβ fibers, show no inhibitory effects to Aβ oligomer toxicity at the equal molar ratio of BAF to Aβ. The inhibition (%) are 
calculated using the same method defined in ‘Materials and methods’. The toxicity assay of Aβ oligomer is described in 
Figure 11—figure supplement 1. The toxicity assay of Aβ fiber is the same as that described in Figure 3.
DOI: 10.7554/eLife.00857.033
Figure 12. Proposed mechanism of how compound binding increases fiber stability and decreases fiber toxicity. 
BAFs (green) bind to the side of amyloid fibers, stabilizing the fiber, and shifting the equilibrium from smaller and 
more toxic oligomers towards fibers. This shift in equilibrium reduces amyloid toxicity.
DOI: 10.7554/eLife.00857.034
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compounds as a function of increasing concentrations of KLVFFA fibers. The general equation for 
deriving the apparent dissociation constant (Kd) is as follows:
For a general reaction of a ligand binding to fibers (containing N monomers):
F(ibril)N + L (igand) ↔FNL.
We estimated the concentration of fibers at any given monomer concentration as:
[F (iber)N] = [Fmomomer] ∗ (1   fiber/N monomers ),
and then we could get:
[FN] =
[F  ] T
N
− [FNL], [L] = [L]T − [FNL], where [F]T is the total monomer concentration, [L]T is the total 
ligand concentration and [FNL] is the concentration of bound fiber;
Kd =
[FN][L]
[FNL]
  and  Kd =
(
[F  ] T
N − [FNL]
)
([L]T − [FNL])
[FNL]
,
and thus
[FNL]2 −
(
[F  ] T
N
+ [L]T +Kd
)
[FNL] +
[F  ] T[L]T
N
=0 .
Figure 13. BAFs bind to in-register β-sheets and are compatible to both parallel and antiparallel amyloid β-sheets. 
A subtlety of our procedure for compound discovery is that it involves both parallel (A) and antiparallel (B) amyloid 
β-sheets. In the X-ray structure of orange G bound to the segment Aβ16–21(KLVFFA) of Aβ, the sheets are antiparallel 
(B). The library of compounds is initially selected based on docking to the antiparallel β-sheet of Aβ16–21. In the next 
step of our procedure, each compound is further screened against the solid-state-NMR-derived model of  
full-length Aβ fiber, which is a parallel sheet (A). The structure models of orange G docked onto Aβ16–21 structure 
and full-length Aβ model are shown in Figure 13—figure supplement 1. As simplified here in (A and B), sulfate 
ions (red) of orange G are respectively hydrogen bonded to two lysine residues (light brown), which keep nearly 
identical geometry (the same ∼9.6 Å distance between the two lysine residues) in either parallel or antiparallel 
sheet. Evidence that orange G, as well as BAF compounds identified by our procedure, all bind to both antiparallel 
and parallel sheets is given by the NMR experiments summarized in Figure 5, where orange G and BAFs are shown 
to bind to both Aβ16–21 and full-length Aβ fibers. Apparently both parallel and antiparallel amyloid β-sheets are 
effective in binding to the same compounds.
DOI: 10.7554/eLife.00857.035
The following figure supplements are available for figure 13:
Figure supplement 1. Structural models of orange G docked onto the antiparallel Aβ16–21 (A) and parallel full-
length Aβ (B) fiber. 
DOI: 10.7554/eLife.00857.036
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Finally, we could get the concentration of bound complex [FNL]:
[FNL] =
(
[F  ] T
N + [L]T +Kd
)
−
√(
[F  ] T
N + [L]T +Kd
)2
− 4[F  ] T[L]TN
2
 (1)
We then applied this equation (1) to our NMR experiments, where we monitored the integrated area 
of each NMR peak (A) of the compounds over a range of KLVFFA fiber concentrations. Assuming the 
complex of the BAF compound with fiber is in fast exchange, the peak area is the average of the peak 
signals for free and bound states, weighted by the fraction of the observed molecule in each state:
A= fLAL + fFNLAFNL .
And the change in NMR peak area (ΔA),
ΔA=AL −A= fFNL (AL −AFNL)
ΔA
(AL −AFNL)
= ΔA
ΔAmax
= ΔA/AL
ΔAmax/AL
= % ΔA
% ΔAmax
= fFNL =
[FNL]
[L]T
ΔA/AL =ΔAmax/AL
(
[F  ] T
N + [L]T +Kd
)
−
√(
[F  ] T
N + [L]T +Kd
)2
− 4[F  ] T[L]TN
2[L]T
.
Hence, the observed fraction of peak area change during the titration of increasing fiber concentration 
against fixed small compound,
fobs = fmax
(
[F  ] T
N + [L]T +Kd
)
−
√(
[F  ] T
N + [L]T +Kd
)2
− 4[F  ] T[L]TN
2[L]T
.
Our structural model suggests that one BAF compound binds three fiber monomers. To obtain the 
Kd, we fit the equation for 1:3 (small molecule:fiber) binding to the NMR titration curve (N = 3), with 
fobs defined as the fraction of peak area decrease 
(
ΔA
AL
)
 for each titration experiment, and fmax defined 
as the fraction maximum of peak area decrease 
(
Amax
AL
)
 for the saturated complex.
MTT cell viability assay
We performed MTT-based cell viability assay to assess the cytotoxicity of Aβ1–42 with or without the 
addition of BAFs and orange G. A CellTiter 96 aqueous non-radioactive cell proliferation assay kit 
(MTT) (Promega cat. #G4100, Madison, WI) was used. HeLa and PC-12 (ATCC; cat. # CRL-1721, 
Manassas, VA) cell lines were used for measuring the toxicity of Aβ1–42. Prior to toxicity test, both HeLa 
and PC-12 cell lines were plated at 10,000 cells per well in 96-well plates (Costar cat. # 3596, 
Washington, DC). HeLa cells were cultured in DMEM medium with 10% fetal bovine serum, PC-12 cells 
were cultured in ATCC-formulated RPMI 1640 medium (ATCC; cat.# 30–2001) with 10% heat-inactivated 
horse serum and 5% fetal bovine serum. Cells were cultured in 96-well plates for 20 hr at 37°C in 5% CO2. 
For Aβ1–42 and BAFs samples preparation, purified Aβ1–42 was dissolved in PBS at the final concentra-
tion of 5 μM, followed by the addition of BAFs at indicated concentrations. The mixtures were 
filtered with a 0.2-μm filter and further incubated for 16 hr at 37°C without shaking for fiber formation. 
To start the MTT assay, 10 μl of pre-incubated mixture was added to each well containing 90 μl medium. 
After 24 hr incubation at 37°C in 5% CO2, 15 μl Dye solution (Promega cat. #G4102) was added into 
each well. After incubation for 4 hr at 37°C, 100 μl solubilization Solution/Stop Mix (Promega cat. 
#G4101) was added to each well. After 12 hr incubation at room temperature, the absorbance was 
measured at 570 nm with background absorbance recorded at 700 nm. Four replicates were measured 
for each of the samples. The MTT cell viability assay measured the percentage of survival cell upon the 
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treatment of the mixture of Aβ1–42 and BAFs. The toxicity inhibition (%) or rescuing percentage (%) of each 
BAF compound was calculated by normalizing the cell survival rate using the PBS buffer-treated cells as 
100% and 0.5 μM (final concentration) Aβ1–42 fiber alone-treated cell as 0% viability.
Transmission electron microscopy (TEM)
TEM was performed to visualize the fibrillation of Aβ1–42 in presence of BAFs. The samples of Aβ1–42 and 
BAFs mixture for TEM measurement were the same as those for MTT assay. For specimen preparation, 
5 μl solution was spotted onto freshly glow-discharged carbon-coated electron microscopy grids (Ted 
Pella, Redding, CA). Grids were rinsed twice with 5 μl distilled water after 3 min incubation, followed by 
staining with 1% uranyl acetate for 1 min. A CM120 electron microscope at an accelerating voltage of 
120 kV was used to examine the specimens. Images were recorded digitally by TIETZ F224HD CCD 
camera.
ThT fibrillation assay
Purified Aβ1–42 was dissolved in 10 mM NaOH at the concentration of 200 μM, followed by sonication for 
further solubilizing Aβ1–42. Aβ1–42 was diluted into PBS buffer at the final concentration of 20 μM, and was 
mixed with 20 μM Thioflavin T (ThT) and different concentrations of BAFs. The reaction mixture was filtered 
with a 0.2 μm filter, split into four replicates and placed in a 96-well plate (black with flat optic bottom). The 
ThT fluorescence signal was measured every 5 min using the Varioskan plate reader (Thermo Fisher 
Scientific, Inc) with excitation and emission wavelengths of 444 and 484 nm, respectively, at 37°C.
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